A Phase 3 interventional study of Letrozole (aromatase inhibitor) and Clomiphene Citrate in Pregnancy and Unexplained Infertility, sponsored by Yale University. Completed at 14 sites in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2015-02-02.
Sponsored by Yale University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing letrozole in Infertility — 2 open to participants now, 3 under way, 2 of them phase 3. Letrozole · Infertility.
Among the 31 studies testing letrozole in Infertility, this one is the 2nd largest by enrollment, is the only one that started in 2010, is one of 10 in phase 3, and was the 6th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →2 of the 31 studies testing letrozole in Infertility are open now, in 2 countries. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 20+ · Women only
University of California, San Francisco · Sites in United States
Ages 18–50 · Women only
By country, each count listing its studies:
Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 13 · Phase 4 6
First in 2004; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 900 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 131 across the 31 interventional studies. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 31 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Yale University has 9 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 31 studies testing letrozole in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this application is to identify a pharmacologic agent which helps couples in whom the female partner ovulates regularly successfully obtain their goal of delivering a healthy child, whose use will result in low rates of multiple gestations. The central hypothesis is that, in infertile ovulatory women undergoing ovarian stimulation (OS) and intrauterine insemination (IUI), the use of aromatase inhibitors (AI) will stimulate the ovaries sufficiently to produce no reduction in the rate of pregnancy, while significantly reducing the numbers of multiple gestational pregnancies that result from stimulation with clomiphene citrate (CC) or follicle stimulating hormone (FSH). The rationale for the proposed research is that reduction of multiple pregnancy rates could significantly reduce maternal and neonatal morbidity and mortality, as well as the cost of healthcare for these individuals and society.
Patient Population
The population will consist of 900 women up to and including women ≥18 to ≤40 years years of age (at time of randomization) desirous of conceiving who will be recruited over approximately a two year period from the Reproductive Medicine Network (RMN) clinical sites and possibly from the Specialized Cooperative Center Programs in Reproductive Research (SCCPIR) sites, through public notification programs.
Study Design
This will be a multi-center, prospective, partially blinded clinical trial of gonadotropins vs. clomiphene citrate vs. aromatase inhibitors. The randomization scheme will be coordinated through the data coordination center (DCC) and the randomization will be stratified by each participating site and within each site for ages 18-34 and 35-40.
Treatment
Patients will be randomized to receive either FSH, CC, or an AI according to randomization tables generated by a computer randomization program. Treatment assignments will be blocked by site and age group. Subjects randomized to pill treatment will receive medication in double blinded fashion, receiving one type of pill (overcoated CC or AI). Subjects randomized to injectable medication(FSH) will receive vials of medication.
Primary efficacy parameter
Multiple gestation rate following recruitment of multiple follicular development with an AI, as compared to CC and FSH.
Secondary efficacy parameters
Rate of pregnancy obtained, live birth rate, and time to pregnancy following administration of an aromatase inhibitor, as compared to CC and FSH as well as the live birth rate of multiple gestation pregnancies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Drug: Letrozole (aromatase inhibitor)
CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Drug: Clomiphene Citrate
A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Drug: Follicle Stimulating Hormone (gonadotropin)
A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.
Time frame: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks
Rate of Pregnancy Obtained
Time frame: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks
Time to Pregnancy
Time frame: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks
Live Birth Rate
Time frame: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks
| Milestone | Aromatase Inhibitors (AI) | Clomiphene Citrate (CC) | Follicle Stimulating Hormone (FSH) |
|---|---|---|---|
| Started | 299 | 300 | 301 |
| Completed | 246 | 251 | 249 |
| Not completed | 53 | 49 | 52 |
| number of multiples | Aromatase Inhibitors (AI) | Clomiphene Citrate (CC) | Follicle Stimulating Hormone (FSH) |
|---|---|---|---|
| Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH. | 9 | 8 | 34 |
| participants | Aromatase Inhibitors (AI) | Clomiphene Citrate (CC) | Follicle Stimulating Hormone (FSH) |
|---|---|---|---|
| Rate of Pregnancy Obtained | 85 | 106 | 140 |
| days | Aromatase Inhibitors (AI) | Clomiphene Citrate (CC) | Follicle Stimulating Hormone (FSH) |
|---|---|---|---|
| Time to Pregnancy | 67.2 ± 55.6 | 67.4 ± 49.8 | 62.3 ± 43.8 |
| participants | Aromatase Inhibitors (AI) | Clomiphene Citrate (CC) | Follicle Stimulating Hormone (FSH) |
|---|---|---|---|
| Live Birth Rate | 56 | 70 | 97 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aromatase Inhibitors (AI) | — | 11/291 (3.8%) | 218/291 (74.9%) |
| Clomiphene Citrate (CC) | — | 12/298 (4%) | 214/298 (71.8%) |
| Follicle Stimulating Hormone (FSH) | — | 25/297 (8.4%) | 217/297 (73.1%) |
| Event | Aromatase Inhibitors (AI) | Clomiphene Citrate (CC) | Follicle Stimulating Hormone (FSH) |
|---|---|---|---|
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 5/291 | 5/298 | 11/297 |
| Congenital anomalyCongenital, familial and genetic disorders | 2/291 | 3/298 | 3/297 |
| HyperemesisGastrointestinal disorders | 0/291 | 0/298 | 2/297 |
| Pregnancy of Unknown LocationPregnancy, puerperium and perinatal conditions | 0/291 | 2/298 | 1/297 |
| Hemorrhagic HematomaInjury, poisoning and procedural complications | 1/291 | 0/298 | 0/297 |
| HypertensionCardiac disorders | 1/291 | 1/298 | 0/297 |
| Hospitalization due to shorness of breath; pulmonary edemaRespiratory, thoracic and mediastinal disorders | 1/291 | 0/298 | 0/297 |
| Neonatal DeathGeneral disorders | 1/291 | 0/298 | 0/297 |
| Presumed PyelonephritisRenal and urinary disorders | 0/291 | 0/298 | 1/297 |
| Pyosalpinx Post IUIReproductive system and breast disorders | 0/291 | 0/298 | 1/297 |
| Event | Aromatase Inhibitors (AI) | Clomiphene Citrate (CC) | Follicle Stimulating Hormone (FSH) |
|---|---|---|---|
| HeadacheNervous system disorders | 122/291 | 104/298 | 89/297 |
| Hot FlashesEndocrine disorders | 49/291 | 92/298 | 25/297 |
| Abdominal BloatingGastrointestinal disorders | 54/291 | 50/298 | 81/297 |
| Breast PainReproductive system and breast disorders | 26/291 | 19/298 | 65/297 |
| Injection Site ReactionGeneral disorders | 9/291 | 6/298 | 32/297 |
| ConstipationGastrointestinal disorders | 8/291 | 28/298 | 6/297 |
| Joint/Limb painMusculoskeletal and connective tissue disorders | 17/291 | 8/298 | 5/297 |
| Age, Continuous(years) | Aromatase Inhibitors (AI) | Clomiphene Citrate (CC) | Follicle Stimulating Hormone (FSH) | Total |
|---|---|---|---|---|
| Mean | 32.2 ± 4.3 | 32.0 ± 4.6 | 32.2 ± 4.1 | 32.2 ± 4.4 |
| Sex: Female, Male(Participants) | Aromatase Inhibitors (AI) | Clomiphene Citrate (CC) | Follicle Stimulating Hormone (FSH) | Total |
|---|---|---|---|---|
| Female | 299 | 300 | 301 | 900 |
| Male | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Aromatase Inhibitors (AI) | Clomiphene Citrate (CC) | Follicle Stimulating Hormone (FSH) | Total |
|---|---|---|---|---|
| United States | 299 | 300 | 301 | 900 |
The record gives a start of Jun 2010, a primary completion of Oct 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Letrozole · Clomiphene · Follicle Stimulating Hormone